MedTrace Logo

Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)

NCT01344707 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2015-04-01

No results posted yet for this study

Summary

The purpose of this study is to determine the Maximum Tolerated Dose, Dose Limiting Toxicities and optimal dosing schedule of 4SC-202 investigating its safety, tolerability and pharmacokinetics.

Conditions

  • Advanced Hematologic Malignancies

Interventions

DRUG

4SC-202

oral administration dose escalation twice daily (bid)or three times a day (tid) continuous dosing for 21 days per cycle

Sponsors & Collaborators

  • 4SC AG

    lead INDUSTRY

Principal Investigators

  • Andreas Engert, Prof. MD · Universitätsklinikum Köln

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01344707 on ClinicalTrials.gov